Completed × NIH × Leukemia, Myelomonocytic, Acute × Clear all Veliparib and Temozolomide in Treating Patients With Acute Leukemia
Phase 1 Completed
66 enrolled
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
Phase 1 Completed
12 enrolled
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 3 Completed
144 enrolled 8 charts
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
61 enrolled 14 charts
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
68 enrolled 11 charts
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
54 enrolled 10 charts
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
41 enrolled 11 charts
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Phase 1/2 Completed
52 enrolled 12 charts
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase 2 Completed
546 enrolled 5 charts
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Completed
19 enrolled 8 charts
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
78 enrolled 10 charts
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
Phase 2 Completed
52 enrolled 17 charts
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
172 enrolled 12 charts
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Phase 2 Completed
24 enrolled 5 charts
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase 2 Completed
197 enrolled 8 charts
Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
Phase 2 Completed
32 enrolled 7 charts
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
45 enrolled 7 charts
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Completed
92 enrolled 10 charts
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
36 enrolled
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
Phase 1 Completed
35 enrolled
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
21 enrolled 8 charts
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Phase 1 Completed
56 enrolled
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Phase 1 Completed
61 enrolled
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
Phase 2 Completed
84 enrolled 7 charts
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 9 charts
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 5 charts
Vorinostat in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
37 enrolled 11 charts
Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
Phase 3 Completed
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 3 Completed
2,000 enrolled
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase 3 Completed
420 enrolled
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase 1 Completed
42 enrolled
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
Phase 1 Completed
30 enrolled
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
Phase 1 Completed
35 enrolled
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 2/3 Completed
2,000 enrolled
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 1 Completed
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
Phase 2 Completed
flt3L in Treating Patients With Acute Myeloid Leukemia
Phase 3 Completed
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase 3 Completed
640 enrolled
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Phase 3 Completed
720 enrolled
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase 1 Completed
25 enrolled
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase 2 Completed
125 enrolled
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
Phase 1 Completed
36 enrolled
XK469R in Treating Patients With Refractory Hematologic Cancer
Phase 1 Completed
60 enrolled
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
30 enrolled
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
296 enrolled
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase 1 Completed
40 enrolled
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 1 Completed
100 enrolled
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
48 enrolled
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
Phase 1/2 Completed
410 enrolled